Xenon Pharmaceuticals Reports Director and Officer Changes
Ticker: XENE · Form: 8-K · Filed: Jan 17, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, officer-changes, director-changes
Related Tickers: XENE
TL;DR
Xenon Pharma (XENE) filed an 8-K for director/officer changes on Jan 17, 2025.
AI Summary
Xenon Pharmaceuticals Inc. filed an 8-K on January 17, 2025, reporting changes related to its board of directors and officers, including the election of directors and potential adjustments to compensatory arrangements. The filing indicates a shift in the company's governance structure.
Why It Matters
Changes in a company's board and executive officers can signal strategic shifts or governance updates that may impact future operations and investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and does not appear to involve significant financial transactions or operational disruptions.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- January 17, 2025 (date) — Date of Report
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of report, suggesting changes in personnel.
Are there any details on new compensatory arrangements?
The filing lists "Compensatory Arrangements of Certain Officers" as an item of report, implying that such arrangements may have been discussed or implemented.
When was this report filed?
The report was filed on January 17, 2025.
What is Xenon Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
What is the company's IRS number?
The IRS Employer Identification Number is 98-0661854.
Filing Stats: 642 words · 3 min read · ~2 pages · Grade level 13.9 · Accepted 2025-01-17 09:01:20
Filing Documents
- xene-20250117.htm (8-K) — 45KB
- 0000950170-25-006495.txt ( ) — 163KB
- xene-20250117.xsd (EX-101.SCH) — 30KB
- xene-20250117_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the "Company") and departed the Company as of such date. In connection with Dr. Von Seggern's departure, he has entered into a Separation Agreement with the Company (the "Separation Agreement") pursuant to which he will receive the severance payments and benefits required under Section P of his offer letter with the Company, dated July 14, 2020, as well as payment of his 2024 annual bonus, based on the Company's Board of Directors' (the "Board") or Compensation Committee of the Board's determination of the corporate performance multiplier for 2024. The Company has also entered into a Consulting Agreement with Dr. Von Seggern (the "Consulting Agreement") pursuant to which he will provide certain services to the Company through May 1, 2025. As consideration for such services, Dr. Von Seggern will receive cash compensation at an hourly rate generally consistent with his prior compensation level, and his equity awards outstanding as of January 17, 2025 will continue to vest until May 1, 2025, or such earlier date as the Consulting Agreement terminates, and the period during which Dr. Von Seggern shall be permitted to exercise his vested equity awards will continue until August 1, 2025. The foregoing descriptions of the Separation Agreement and the Consulting Agreement do not purport to be complete and are qualified in their entirety by reference to the Separation Agreement and Consulting Agreement, which will be filed as exhibits to the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: January 17, 2025 By: /s/ Sherry Aulin Sherry Aulin Chief Financial Officer